IONIQ Sciences Designated “Leading Pioneer in Non-Invasive Lung Cancer Testing” by Global Health and Pharma
IONIQ Sciences has been designated a “Leading Pioneer in Non-Invasive Lung Cancer Testing” for the year 2021 by Global Health and Pharma. This award was given to us based on our pioneering efforts in using bioimpedance to catch cancer in its earliest stages. Our breakthrough-designated IONIQ ProLung Test™ is serving as the foundation for our vision to create a non-invasive, multicancer screen at the point-of-care (POC). The confluence of Electrical Impedance Analytics (EIA) and Artificial Intelligence is the key to understanding the body’s early warning system to the presence of cancer, and it has the potential to save countless lives and significantly reduce the financial burden of healthcare. External recognition like this inspires our passionate team and growing Scientific Advisory Committee in our efforts to modernize cancer detection.